Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe Graves’ orbitopathy

Liyun Shen1,2,*, Lei Ye1,2,*, Wei Zhu1,*, Qin Jiao3,*, Yulin Zhou1,2, Shu Wang1,2, Weiqing Wang1,2 and Guang Ning1,2

1Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3Department of Ophthalmology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Correspondence should be addressed to S Wang or W Wang: shuwang999@hotmail.com or wqingw61@163.com

*(L Shen, L Ye, W Zhu and Q Jiao contributed equally to this work)

Abstract

Objective: A combination of glucocorticoids with mycophenolate is recommended by current guidelines to boost response to Graves’ orbitopathy (GO) therapy. This study was designed to evaluate the therapeutic effects and safety of methotrexate (MTX) plus reduced (3.0 g) or full-dose (4.5 g) i.v. methylprednisolone (MP) vs full-dose i.v. MP alone. Design and methods: This was a prospective, randomized, observer-masked, single-center clinical trial conducted in a tertiary clinical center. Ninety-seven patients with active moderate-to-severe GO were screened and 90 patients underwent randomization between April 2018 and Oct 2019. All patients completed 12 weeks of treatment and received clinical assessment. The patients received either MP 4.5 g only, MP 4.5 g plus oral MTX, or MP 3.0 g plus oral MTX. The primary outcome was the CAS response at week 12. Secondary outcomes were adverse events and other individual ophthalmic parameters. Results: At week 12, 53.3% of MP, 76.7% of reduced MP plus MTX, and 76.7% of MP plus MTX achieved a CAS response, although the difference was not significant ($P = 0.1$). The overall response rates of the MP group, the reduced MP plus MTX group, and the MP plus MTX group were 43.3%, 53.3%, and 60%, respectively ($P = 0.5$). Subgroup analysis found that smoking status interacted with marginal significance with treatment effect ($P = 0.048$). Importantly, adverse event incidence was significantly lower in the reduced MP + MTX group ($P = 0.017$). Conclusions: Our study shows that reduced MP plus MTX therapy is effective and safer in treating active and moderate-to-severe GO patients than 4.5 g MP monotherapy.

Key Words
- methotrexate
- steroid-sparing agent
- reduced steroids
- Graves’ orbitopathy
- RCT
- adverse event

**European Thyroid Journal**

© 2022 The authors
Published by Bioscientifica Ltd.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Introduction

Graves' orbitopathy (GO) is the most common orbital disease in adults, which greatly affects patients' quality of life (1, 2, 3). Although bioagents such as teprotumumab showed a promising new paradigm in GO treatment (4, 5, 6), guidelines recommended that a 4.5 g weekly pulse i.v. methylprednisolone (ivMP) remains to be the more accessible and cost-effective choice for active and moderate-to-severe GO patients currently (7). In previous studies, the response rate of MP monotherapy was around 30–80% (8, 9, 10). Though efficacy increased with dosage, MP dosage should not exceed 8 g for the safety concerns (7, 8). The increased dose is accompanied by increased side effects including hypertension, infection, diabetes, osteoporosis, liver dysfunction, or electrolyte imbalance. Therefore, adding a second drug to reduce the dose of glucocorticoids is justified.

Methotrexate (MTX) has long been used as a steroid-sparing agent that elicits anti-inflammatory and immunomodulatory effects with chronic low-dose treatment in many autoimmune diseases. A study used MTX alone as second-line therapy in GO patients who failed to respond to MP and found that 29% achieved a VISA (vision loss, inflammation, strabismus, appearance) inflammatory score <3 within a mean of 3 months of treatment, indicating its direct anti-inflammatory effect in treating GO (11). A retrospective study reported a step-down approach using MTX as a steroid-sparing agent in combination with MP and achieved reduced MP total dosage to inactivate GO within an average of 13 months (12, 13, 14). MTX could upregulate GRα (glucocorticoid receptor α) expression (15), the active subtype of glucocorticoid receptor, which may theoretically enhance glucocorticoid effect. However, evidence from the prospective study has been lacking.

In this study, we conducted a 12-week prospective, randomized, observer-masked, single-center clinical trial to compare the combination therapy of reduced or 4.5 g MP plus MTX vs 4.5 g MP monotherapy in treatment efficacy of clinical activity score (CAS) response and analyze the safety profiles.

Methods

Trial design

This was a prospective, randomized, observer-masked, single-center clinical trial. The patients were consecutively enrolled between April 2018 and October 2019. Patients aged 18–65 years diagnosed as active moderate-to-severe GO in our clinical center were included in this study. The diagnosis was based on the EUGOGO consensus. Patients should not have received any immunosuppressive therapy or radiotherapy or decompression surgery in the previous 3 months. Patients with abnormal heart, liver, and kidney function, other known autoimmune diseases, or with malignancy were excluded from the study. The board of medical ethics of Ruijin Hospital approved the study, and all patients gave their written informed consent. This trial is registered with the Chinese Clinical Trial Registry, ChiCTR1800015912.

Patient randomization was generated in random block size with an allocation ratio of 1:1:1 for three groups: MP group (group 1), reduced MP plus MTX group (group 2), and MP plus MTX group (group 3).

MP was given as ivMP 0.5 g per week for 6 weeks followed by ivMP 0.25 g for 6 weeks. Reduced MP was given as ivMP 0.25 g per week for 12 weeks. MTX was given orally on the next day following ivMP as 10 mg per week for the first 2 weeks and then added to 12.5 mg per week for 10 weeks. Folic acid 5 mg was given orally once a week following the next day of MTX for 12 weeks (Fig. 1). The observer ophthalmologist (QJ) was blinded to the treatment groups. Patients should not inform the ophthalmologist about the medication they received.

Outcome evaluation

Primary outcome was the CAS response at the end of therapy (12th week). Secondary outcomes were the adverse events (AEs) and other individual ophthalmic parameters. We also examined the overall response at week 12 as a post hoc outcome.

All patients underwent ophthalmic, endocrine, and safety assessments at baseline, 6th week, and 12th week. Ophthalmic examinations were performed by a single ophthalmologist (QJ) who was blinded to the treatment. CAS, proptosis, eyelid width, Gorman diplopia score, intraocular pressure (IOP), and visual acuity were recorded by using the modified EUGOGO patient form. A Hertel exophthalmometer was used for the measurement of proptosis, and the upper limit of normal Chinese in our study was 18.6 mm. Active was defined when ≥3 of the 7-point CAS (spontaneous retrobulbar pain, pain on attempted eye movements, conjunctival hyperemia, eyelid redness, chemosis, swelling of the caruncle, and swelling of the eyelids) features were present. Improvement was defined as CAS decreased by at least 2 points, proptosis reduction by at...
least 2 mm, reduction of lid width by at least 2 mm, degrade of Gorman score (from constant to inconstant, inconstant to intermittent, and intermittent to absent), degradation in any of the class 2 signs of NOSPECS by at least 2 grades, IOP reduced by at least 2 mmHg, and visual acuity improved by 1 Snellen line. Exacerbation was defined as increase by the same extent in the above parameters. Responsiveness was defined as improvement in at least one eye without exacerbation in the other eye. Deterioration was defined as exacerbation in at least one eye without improvement in the other eye. Conditions that fit in neither responsiveness nor deterioration were defined as unchanged. The overall response was defined as being responsive in at least two of the four ophthalmic parameters including CAS, proptosis, lid width, and Gorman score.

Whole blood count, body weight, blood pressure (BP), blood glucose, blood lipid, liver function, electrolytes, urea, urinalysis, and bone mineral density (BMD) were assessed to monitor treatment-associated agranulocytosis, weight gain, bone loss or osteoporosis, hypertension, diabetes, hyperlipidemia, impaired liver function, hypokalemia, hyperuricemia, and urinary tract infection. Any self-reported medical events were also counted. Common Terminology Criteria for Adverse Events (CTCAE) ver.5.0 was used to grade AE severity. Dual-energy X-ray absorptiometry (GE-Lunar Prodigy; GE Healthcare) was used to measure BMD (grams per square centimeter) in the lumbar spine, femoral neck, and hip of all subjects at baseline and week 12. AE that occurred in weeks 6 and 12 are evaluated below as follows: (i) body weight increased by more than 2.5%, 5% of baseline in the 12th week compared to baseline; since 5% increase was grade 1 in CTCAE, only 5% increase was counted into total AE; (ii) development of the following: diabetes mellitus is defined as fasting glucose ≥7 mmol/L or 2-h glucose ≥11.1 mmol/L after oral glucose tolerance test or glycated hemoglobin (HbA1C) ≥6.5%, with baseline fasting glucose <5.6 mmol/L and 2-h glucose <7.8 mmol/L and HbA1C <5.7%; (iii) development of hypertension is defined as systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg with normal BP at baseline; (iv) hypokalemia is defined as serum potassium < 3.5 mmol/L with normal potassium at baseline; (v) hyperuricemia is defined as serum uric acid >420 μmol/L (for man) or >360 μmol/L (for woman) with normal urea at baseline; (vi) liver function impairment is defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than upper normal limits with normal ALT and AST at baseline; (vii) development of
hyperlipidemia as evaluated according to CTCAE criteria; and (viii) neutropenia is defined as neutrophil count < 2 × 10^9/L and severity was graded by CTCAE criteria. BMD was assessed at baseline and week 12. BMD of L1–4, femoral neck, and total hip is represented by T score. Osteoporosis is defined as either one of the three T scores ≤−2.5. Bone loss is defined as −2.5 < T < −1.0 according to the World Health Organization criteria (1994).

The study prespecified outcomes did not involve quality of life (QoL), but most of the participants completed QoL assessment at outpatient follow-up. EUGOGO quality of life questionnaires (GO-QoL) were filled out by patients at baseline and week 12, which consists of two subscales: visual function and appearance (16). The questions were answered on a 3-point scale (1 = severely limited; 2 = a little limited; 3 = not limited at all). The points given to questions 1–8 and 9–16 was summed to yield 2 raw scores ranging from 8 to 24 points. The 2 raw scores are then transformed into 2 total scores from 0 to 100 by the formula: (total scores – #)/(2 × #) × 100, where # represents the number of completed items. For both scores, 0 indicated the worst possible health state and 100 indicated the best possible health state. QoL improvement was defined as increase by 6 points or more (17, 18).

Statistical methods

The sample size was calculated based on previous studies, assuming that add-on MTX could achieve 91% CAS response, compared with 60% for MP monotherapy (10, 11). The sample size of 29 patients per group was estimated to provide the trial with 80% power to detect such difference at a two-sided alpha level of 0.05.

Continuous variables are expressed as the mean ± s.d. or median and quartiles; categorical variables are expressed as frequency and percentage. Values of serum free tri-iodothyronine, free thyroxine, thyroid-stimulating hormone (TSH), TSH receptor autoantibodies (TRAb), thyroid peroxidase antibody, and thyroglobulin antibody are shown as median and quartiles of the original values and log10 normal transformed before statistical analysis. For each patient, the worst value of the two eyes was presented for each ophthalmological parameter. Student’s t-test was used to compare continuous variables, and a Mann–Whitney U-test was used for comparing CAS. χ² test or Fisher’s exact test was used for comparing proportions. Post hoc subgroup analyses were tested for interaction in logistic model of CAS response at week 12. Subgroup specific odds ratios and 95% CIs are presented as a forest plot. QoL was analyzed post hoc by both intention-to-treat analysis, which analyzed the full data set, and per-protocol analysis, which analyzed patients with QoL questionnaires. P-values were two-sided and the significance level was set at 0.05. All analyses were performed with Statistical Analysis System (SAS) software for Windows, version 9.4 (SAS Institute Inc) and Prism 9 for Windows, version 9.0 (GraphPad Software Inc).

Results

Patient characteristics

A total of 97 consecutive patients were screened and 90 patients underwent randomization (Fig. 2). Each group was assigned 30 patients. Baseline clinical characteristics were not significantly different among the three groups (Table 1). Patients were mostly female (66.7–76.7%) with a median CAS of 4–4.5 and a median disease duration of 6–7.5 months. There were 26 patients who received glucocorticoids (i.v., oral, and orbital) at least 3 months prior to treatment and 1 patient who received strabismus surgery 7 months prior to the study in group 1 (4.5 g MP). No patient underwent orbital radiotherapy prior to the study. All patients completed 12 weeks of treatment and received clinical assessment at week 6 and week 12.

Ophthalmic assessment and outcome evaluation

CAS score decreased significantly in all three groups after treatment (Fig. 3A). There was no significant difference between groups at week 6 or 12. In group 1, the peak CAS response rate was 56.7% at week 6 and decreased to 53.3% at week 12 (Fig. 3B and Table 2). While in groups with MTX, CAS response rate continuously increased and reached 76.7% at week 12. At the 12th week, numerically more patients achieved CAS response in MTX groups (Fig. 3B), although the difference was not significant. The inactive (CAS <3) rates after treatment at week 12 were 63.3% in MP monotherapy, 66.7% in reduced MP plus MTX, and 70% in MP plus MTX (Supplementary Table 1, see section on supplementary materials given at the end of this article).

To further clarify whether stratification factors affect treatment efficacy, subgroup analysis of CAS response at week 12 was performed post hoc according to variables such as age, gender, duration, smoking status, baseline CAS, and TRAb level. Patients who were male, duration > 6 months, or smoking achieved a higher CAS response rate after reduced MP plus MTX treatment. Interaction analysis found that only smoking status was significant (OR: 9.64 (1.64,56.9), P = 0.048) between group 1 and
group 2. Smoking may interact with the treatment regimen to affect CAS response. Patients who had smoking exposure might be more likely to achieve CAS response with reduced MP plus MTX treatment. While comparing group 1 with group 3, no subgroup difference was found.

The response rate of other individual ophthalmic parameters did not show significant differences among groups (Table 2). Numerically group 3 achieved the highest overall response rate of 60%, followed by group 2 (53.3%) and group 1 (43.3%) (Table 2, \( P = 0.5 \)).

Because CAS response in the MP group plateaued at week 6, we compared the TRAb difference among groups. TRAb was significantly suppressed in all three groups both at week 6 and week 12, while no difference was found among the three groups in regards to the suppression rate and differences, although groups with MTX had a slightly larger difference (Supplementary Fig. 1A and B).

QoL scores were analyzed post hoc. There were 22/30 patients, 21/30 patients, and 19/30 patients who fulfilled the QoL evaluation at baseline and week 12. QoL scores significantly increased in both visual function and appearance after treatment in all three groups: 73–84% patients improved on the visual function scale, and 86–91% improved on the appearance scale. No significant difference was found among groups (Table 2).

There were 26/30 (86.7%) in group 1, 22/30 (73.3%) in group 2, and 23/30 (76.7%) in group 3 who visited the same ophthalmologist at week 24. One non-responsive patient from the MP + MTX group developed dysthyroid optic neuropathy (DON) at week 12 and received decompression surgery 2 weeks later. This patient initially improved at week 6 with increased visual acuity and degraded diplopia while DON occurred by week 12. CAS was not decreased throughout treatment. Relapse occurred in 1 responder (1/23, including 6 responders who lost follow-up) in the MP + MTX group at week 24. At week 36, further relapses occurred in 1 patient (1/16, including 3 patients who lost follow-up) in the MP group and 2 patients (2/23) in the MP + MTX group. Of the 20 CAS non-responders with CAS \( \geq 3 \) at week 12, 10 were from the MP group, 5 from reduced MP + MTX, and 5 from MP + MTX (including 1 lost follow-up). Among them, 3 patients in the MP group
(3/10, 33.3%), and 2 patients in each of the 2 MTX groups (2/5, 40%) became CAS responders at week 24. Seven patients underwent second therapy in 6 months: 1 from group 1, 1 from group 2, and 4 from group 3.

**Adverse event**

All AEs were mild to moderate, and no patient discontinued treatment (Table 3). There were significantly fewer AEs in reduced MP plus MTX group (21 in group 2, 41 in group 1, 38 in group 3, \(P=0.017\), Table 3).

The most prevalent AE was new-onset dyslipidemia, which was more frequently reported in group 1 and group 3 (50%) but with no significant difference among groups (Table 3). Compared to standard MP monotherapy, group 2 had significantly fewer new-onset hypokalemia at week 6 (\(P=0.02\)) and less weight gain at week 12 (\(P=0.04\)). New-onset hypertension occurred more frequently in group 1 compared to group 3 both at week 6 and week 12 (at week 6: \(P=0.047\); at week 12: \(P=0.02\)). MTX-related AEs such as neutropenia were noted in 1 patient in group 2 (grade 2) and 3 patients in group 3 (grade 1).

| Table 1  | Baseline clinical characteristics. |
|----------|-----------------------------------|
|          | **MP (G1)** | **Reduced MP + MTX (G2)** | **MP + MTX (G3)** | **P-value (overall)/G1 vs G2/G1 vs G3** |
| \(N\)    | 30          | 30                       | 30               | 0.9/0.7/0.7                                   |
| Age (year) | 46.5 (35–52) | 46 (37–53)               | 46.5 (39–53)    | 0.8/0.8/1                                    |
| Gender (female %) | 21 (70%) | 23 (76.7%)                | 20 (66.7%)      | 0.4/0.9/1                                    |
| Weight (kg) | 62.5 ± 9.8 | 62.3 ± 9.8                | 65.6 ± 11.0     | 0.8/0.9/0.3                                  |
| BMI       | 23.5 ± 3.1  | 23.6 ± 3.2                | 23.9 ± 2.5      | 0.6/0.6/0.3                                  |
| Systolic blood pressure (mm Hg) | 123.8 ± 17.6 | 126.5 ± 17.6           | 128.7 ± 18.2   | 0.3/1/0.2                                    |
| Diastolic blood pressure (mm Hg) | 72.9 ± 13.5 | 72.9 ± 8.5                | 76.9 ± 9.7      | 1/1/0.8                                      |
| Hypertension (n, %) | 6 (20%) | 7 (23.3%)                  | 8 (26.7%)       | 0.8/1/0.5                                    |
| Diabetes (n, %) | 0     | 1 (3.3%)                   | 2 (6.7%)        | 1/1/0.8                                      |
| Hyperlipidemia (n, %) | 9 (30%) | 8 (26.7%)                  | 9 (30%)         | 0.7/0.8/0.8                                  |
| Smoking history (n, %) | 0     | 2 (6.7%)                   | 0               | 1/1/0/8                                      |
| Current smoker | 13 (43.3%) | 13 (43.3%)                | 10 (33.3%)      | 0.2/0.1/0                                    |
| Passive smoker | 13 (43.3%) | 13 (43.3%)                | 10 (33.3%)      | 0.2/0.1/0                                    |
| Ex-smoker | 3 (10%)     | 2 (6.7%)                   | 3 (10%)         | 0.8/1/1                                      |
| Never-smoker | 14 (46.7%) | 13 (43.3%)                 | 17 (56.7%)      | 0.8/1/1                                      |
| History of thyroid disease | | | | |
| Graves' hyperthyroidism | 29 (96.7%) | 30 (100%)                  | 30 (100%)       | 1/1/1                                         |
| Primary hypothyroidism | 0 | 0                          | 0               | -                                             |
| TPOAb or TGAAb positive | 14 (46.7%) | 21 (70%)                   | 15 (50%)        | 0.2/0.1/1                                    |
| Previous antithyroid treatments | | | | |
| Anti-thyroid drugs | 27 (90%) | 28 (93.3%)                 | 27 (90%)        | 1/1/1                                         |
| Radioiodine | 6 (20%) | 8 (26.7%)                   | 5 (16.7%)       | 0.7/0.8/1                                    |
| Thyroidectomy | 1 (3.3%) | 0                          | 1 (3.3%)        | 1/1/1                                         |
| Current thyroid treatments | | | | |
| None | 2 (6.7%) | 2 (6.7%)                   | 2 (6.7%)        | 1/1/1                                         |
| Levothyroxine only | 6 (20%) | 5 (16.7%)                  | 2 (6.7%)        | 0.4/1.0/3                                    |
| Tapzole only | 5 (16.7%) | 10 (33.3%)                 | 7 (23.3%)       | 0.4/0.2/0.8                                  |
| PTU only | 1 (3.3%) | 0                          | 1 (3.3%)        | 1/1/1                                         |
| Levothyroxine and tapzole | 12 (40%) | 12 (40%)                   | 14 (46.7%)      | 0.9/1.0/8                                    |
| Levothyroxine and PTU | 4 (13.3%) | 1 (3.3%)                   | 4 (13.3%)       | 0.4/0.4/1                                    |
| Euthyroid (n, %) | 23 (76.7%) | 25 (83.3%)                 | 23 (76.7%)      | 0.9/0.8/1                                    |
| Duration of eye symptoms (months) | 6 (4–11) | 7.5 (5–11)                 | 6.5 (5–12)      | 0.3/0.2/0.7                                  |
| Previous GO treatment (n, %) | 9 (30%) | 10 (33.3%)                 | 8 (26.7%)       | 0.9/1/1                                      |
| sTSH | 0.3 (0.0–1.3) | 0.1 (0.0–0.7)              | 0.3 (0.0–1.4)  | 0.7/0.4/0.6                                   |
| FT3 | 4.7 (4.0–5.3) | 4.5 (4.0–5.1)              | 4.4 (4.0–5.1)  | 1/0.9/0.8                                    |
| FT4 | 12.6 (10.6–13.8) | 12.6 (11.37–15.08)        | 12.8 (11.8–14.1) | 0.1/0.7/0.2                                   |
| TRAb | 6.2 (2.2–20.5) | 9.6 (3.23–21.92)         | 10.1 (3.2–26.8) | 0.6/0.4/0.4                                  |
| TPOAb | 2.9 (0.4–363.6) | 21.6 (1.13–162.45)        | 7.7 (0.6–322.4) | 0.9/0.6/0.8                                  |
| Lid erythema (n, %) | 3 (10%) | 3 (10%)                    | 2 (6.7%)        | 1/1/1                                         |
| Chemosis (n, %) | 22 (73.3%) | 21 (70%)                   | 26 (86.7%)      | 0.3/0.1/0                                    |
| Caruncle swelling (n, %) | 20 (66.7%) | 17 (56.7%)                 | 18 (60%)        | 0.8/0.6/0.8                                  |
| CAS | 4.5 (3-5) | 4 (3-5)                    | 4 (4-5)         | 0.6/0.3/0.6                                  |

The worst value of the two eyes was presented for each ophthalmological parameter.

https://doi.org/10.1530/ETJ-22-0017
Published by Bioscientifica Ltd.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Discussion

In this study, we provided the first randomized controlled trial (RCT) evidence to demonstrate that reduced MP (3.0 g) plus MTX therapy achieved a similar CAS response with fewer steroid-relevant AEs, compared to the standard 4.5 g MP regimen in active moderate-to-severe GO patients.

The combination of glucocorticoids with steroid-sparing agents has been explored in previous studies to boost response to GO therapy. Successful therapies such as the combination of ivMP and mycophenolate (19), the addition of azathioprine to oral prednisolone (20, 21), or the combination of oral glucocorticoids and cyclosporine (22, 23) all showed favorable response compared to monotherapy and are recommended by the current guideline (7), while the dose of steroid in those studies was not reduced. In a retrospective study, MTX was used concomitantly with ivMP in 23 patients for an average duration of 13 months and led to a reduced cumulative dose of ivMP (mean: 2.72 g) to inactive the disease, indicating that MTX could lower the dose of MP; however, the treatment took 13 months in average, and the study lacks ivMP monotherapy as control (12). This is the first prospective RCT study comparing reduced MP plus steroid-sparing agent to MP monotherapy with matched 12-week time course. Importantly, we found that reduced MP (3.0 g) plus MTX therapy achieved a similar CAS response as standard MP monotherapy.

The clinical course of GO was characterized by a self-limiting inflammatory stage accompanied by gradually prevailing fibrotic reconstruction. Therefore, treatment should be able to rapidly inactivate the inflammation to prevent reconstructive progression. When used in other noninfectious ocular diseases, the median time for MTX to achieve control of inflammation with corticosteroids tapered to 10 mg or less daily, ranging from 4.5 months to 9 months (24, 25). In this study, we investigated the MTX’s steroid-sparing effect in a 12-week short period to match with the guideline-recommended 4.5 g MP therapy. Compared to 4.5 g MP therapy, responders to combined treatment continued to increase after week 6, indicating MTX’s add-on efficacy in short-term treatment. Based on the current result and previous studies on combination therapy, extended use of MTX to 24 weeks might be beneficial to lift the response rate and prevent relapse at week 24.

MTX used in this study was 12.5 mg/week, which is the typical dose in the range of low-dose MTX (26, 27, 28). Low-dose MTX treatment inhibits purine synthesis in primary human T lymphocytes from rheumatoid arthritis (RA) patients, halting the proliferation of mitogen-stimulated T cells (29). MTX also leads to the increase of intracellular adenosine level, which is a potent anti-inflammatory mediator acting via interactions with a variety of immune-cell subtypes including neutrophils, macrophages, and T cells (30), resulting in a reduction of pro-inflammatory cytokines interleukin (IL)-1β, TNF-α, and IL-6 and reduced matrix metalloproteinases production (31). The effect of MTX on RA synovial fibroblasts/T cells cross-talk signals was suggested to be mediated by adenosine release and decreased cell adhesion (26, 32). In our study, we found that TRAb was suppressed in all three groups during treatment, while both the suppression rate and the differences between baseline and 12th week were slightly higher in MTX groups (Supplementary Fig. 1A and B).

Interestingly, our findings suggest that reduced MP plus MTX is a well-tolerated treatment option as this group showed a significantly lower AE incidence rate. AEs were mild to moderate and mostly steroid-related, such as new-onset dyslipidemia, new-onset hypokalemia, and weight gain were mostly seen in 4.5 g MP monotherapy, which could be explained by the larger dose of steroid used. We noted that new-onset dyslipidemia was the most common AE related to treatment in our study.
Table 2  Treatment responses.

| Parameters          | MP (G1) Baseline | Post-treatment | P-value | MP (G2) Baseline | Post-treatment | P-value | MP (G3) Baseline | Post-treatment | P-value | P-value overall/ G1 vs G2/ G1 vs G3 |
|---------------------|------------------|----------------|---------|------------------|----------------|---------|------------------|----------------|---------|-----------------------------------|
| CAS score           | 4.5 (3–5)        | 2 (1–4)        | <0.0001 | 4 (3–5)          | 2 (1–3)        | <0.0001 | 4 (4–5)          | 2 (1–3)        | <0.0001 | 0.1/0.1/0.1                      |
| Responsive          | 16 (53.3%)       | 12 (40%)       |         | 23 (76.7%)       | 7 (23.3%)      |         | 23 (76.7%)       | 7 (23.3%)      |         |                                   |
| Unchanged           | 13 (46.7%)       | 10 (33.3%)     |         | 2 (6.7%)         | 1 (3.3%)       |         | 2 (6.7%)         | 1 (3.3%)       |         |                                   |
| Deteriorated        | 0                | 0              |         | 0                | 0              |         | 0                | 0              |         |                                   |
| Lid edema           | None             | 0              | 0.005   | 1 (3.3%)         | 0              | 0.283   | 0 (3.3%)         | 0              | 0.5     |                                   |
| Mild                | 11 (36.7%)       | 16 (53.3%)     |         | 22 (73.3%)       | 22 (73.3%)     |         | 14 (46.7%)       | 19 (63.3%)     |         |                                   |
| Moderate            | 17 (56.7%)       | 12 (40%)       |         | 7 (23.3%)        | 7 (23.3%)      |         | 13 (43.3%)       | 10 (30%)       |         |                                   |
| Severe              | 2 (6.7%)         | 1 (3.3%)       |         | 1 (3.3%)         | 1 (3.3%)       |         | 2 (6.7%)         | 1 (3.3%)       |         |                                   |
| Responsive          | 2 (6.7%)         | 0              |         | 0                | 0              |         | 1 (3.3%)         | 0              | 0.3     | 0.8/0.5/1                        |
| Unchanged           | 28 (93.3%)       | 30 (100%)      |         | 0                | 0              |         | 29 (96.7%)       | 0              |         |                                   |
| Deteriorated        | 0                | 0              |         | 0                | 0              |         | 0                | 0              |         |                                   |
| Conjunctival hyperemia | 0               | 2 (6.7%)       | 0.05    | 11 (36.7%)       | 11 (36.7%)     |         | 1 (3.3%)         | 7 (23.3%)      | 0.01    |                                   |
| Responsive          | 30 (100%)        | 25 (83.3%)     |         | 28 (93.3%)       | 15 (50%)       |         | 23 (76.7%)       | 18 (60%)       |         |                                   |
| Unchanged           | 5 (16.7%)        | 10 (33.3%)     |         | 10 (33.3%)       | 7 (23.3%)      |         | 23 (76.7%)       | 23 (76.7%)     |         |                                   |
| Deteriorated        | 25 (83.3%)       | 20 (66.7%)     |         | 20 (66.7%)       | 12 (40%)       |         | 12 (40%)         | 9 (30%)        |         |                                   |
| Proposis (mm)       | 22.3 ± 2.3       | 21.4 ± 2.4     | 0.027   | 21.6 ± 2.1       | 20.8 ± 2.5     | 0.007   | 22.0 ± 2.7       | 21.6 ± 2.8     | 0.1     |                                   |
| Responsive          | 10 (33.3%)       | 10 (33.3%)     |         | 10 (33.3%)       | 7 (23.3%)      |         | 9 (30%)          | 15 (50%)       | 0.9     | 0.9/1/0.9                        |
| Unchanged           | 16 (53.3%)       | 17 (56.7%)     |         | 17 (56.7%)       | 17 (56.7%)     |         | 15 (50%)         | 18 (60%)       |         |                                   |
| Deteriorated        | 4 (13.3%)        | 3 (10%)        |         | 3 (10%)          | 2 (6.7%)       |         | 6 (20%)          | 5 (16.7%)      |         |                                   |
| Lid width (mm)      | 11.8 ± 2.0       | 11.7 ± 2.3     | 0.7     | 12.0 ± 1.9       | 12.4 ± 1.6     | 0.1     | 11.6 ± 1.7       | 11.8 ± 1.9     | 0.8     | 0.9/0.9/1                        |
| Responsive          | 8 (26.7%)        | 7 (23.3%)      |         | 7 (23.3%)        | 7 (23.3%)      |         | 7 (23.3%)        | 7 (23.3%)      |         |                                   |
| Unchanged           | 17 (56.7%)       | 15 (50%)       |         | 15 (50%)         | 15 (50%)       |         | 18 (60%)         | 18 (60%)       |         |                                   |
| Deteriorated        | 6 (20%)          | 8 (26.7%)      |         | 6 (20%)          | 8 (26.7%)      |         | 5 (16.7%)        | 5 (16.7%)      |         |                                   |
| Diplopia (Gorman)   | 0.2              | 0.9            |         | 0.9              | 0.9            |         | 0.9              | 0.9            |         |                                   |
| Absent              | 9 (30%)          | 15 (50%)       |         | 18 (60%)         | 20 (66.7%)     |         | 20 (66.7%)       | 14 (46.7%)     |         | 0.4/0.2/0.6                     |
| Intermittent        | 3 (10%)          | 6 (20%)        |         | 4 (13.3%)        | 5 (16.7%)      |         | 5 (16.7%)        | 6 (20%)        |         |                                   |
| Inconstant          | 7 (23.3%)        | 4 (13.3%)      |         | 3 (10%)          | 2 (6.7%)       |         | 3 (10%)          | 3 (10%)        |         |                                   |
| Constant            | 11 (36.7%)       | 5 (16.7%)      |         | 5 (16.7%)        | 3 (10%)        |         | 10 (33.3%)       | 7 (23.3%)      |         |                                   |
| With diplopia at baseline |  |                    |         | 6 (50%)          | 12 (40%)       |         | 8 (44.4%)        | 0.4/0.2/0.6    |         |                                   |
| Responsive          | 12 (57.1%)       | 6 (50%)        |         | 6 (50%)          | 6 (50%)        |         | 8 (44.4%)        | 0.4/0.2/0.6    |         |                                   |
| Unchanged           | 9 (42.9%)        | 4 (33.3%)      |         | 4 (33.3%)        | 9 (50%)        |         | 9 (50%)          | 0.4/0.2/0.6    |         |                                   |
| Deteriorated        | 0                | 2 (16.7%)      |         | 2 (16.7%)        | 1 (5.6%)       |         | 1 (5.6%)         | 0.4/0.2/0.6    |         |                                   |
| Without diplopia at baseline | |                  |         | 0                | 0              |         | 0                | 0.3/0.5/0.2    |         |                                   |
| Responsive          | 0                | 0              |         | 0                | 0              |         | 0                | 0.3/0.5/0.2    |         |                                   |
| Unchanged           | 9 (100%)         | 16 (88.9%)     |         | 2 (11.1%)        | 3 (25%)        |         | 3 (25%)          | 3 (25%)        |         |                                   |
| Deteriorated        | 0                | 0              |         | 0                | 0              |         | 0                | 0.3/0.5/0.2    |         |                                   |
| Intraocular pressure (mmHg) | 20.6 ± 4.6      | 19.8 ± 4.5     | 0.2     | 20.6 ± 4.5       | 20.1 ± 4.9     | 0.5     | 19.5 ± 4.3       | 19.9 ± 5.1     | 0.7     | 0.05/1/0.05                      |
| Responsive          | 14 (46.7%)       | 14 (46.7%)     |         | 14 (46.7%)       | 14 (46.7%)     |         | 10 (33.3%)       | 16 (53.3%)     |         |                                   |
| Unchanged           | 7 (23.3%)        | 6 (20%)        |         | 6 (20%)          | 6 (20%)        |         | 16 (53.3%)       | 16 (53.3%)     |         |                                   |

(Continued)
Since accumulated evidence suggests that dyslipidemia is associated with GO development (33, 34, 35), cholesterol levels should be monitored in practice. The frequency of measuring BMD in our study (12-week interval) may have little long-term significance. However, the purpose of reassessing BMD was not to assess fracture risk, but to assess early BMD loss and its association with different treatment regimens. Therefore, in this study, we re-evaluated BMD at week 12. In groups with the same MP dosage, significantly fewer new-onset hypertension occurred in MP plus MTX group compared to MP monotherapy. This was in line with MTX usage in RA studies in which MTX treatment was associated with significantly lower clinic and 24-h peripheral and central BP compared to those who did not take MTX (36). The BP reducing effect was explained by MTX protection against stiffness-mediated BP increase (37). As for the screen of GC-induced diabetes (38, 39), the incidence of new-onset diabetes was low and without significant differences among groups in this study. MTX-related AE such as neutropenia was present in four patients and were ameliorated by leucogen tablets. Importantly, MTX use warrants monitoring infrequent but clinically serious AEs, particularly hepatic, pulmonary, and hematologic toxicity (40). In our study, patients with known risk factors that would lead to severe AE were excluded, such as liver or renal impairment, history of hepatitis or tuberculosis, and history of malignancy, and AEs were closely monitored every 6 weeks. We observed neutropenia in 4 patients (1/30 in reduced MP + MTX, 3/30 in MP + MTX group) and were all timely relieved by leucogen tablets. Therefore, under careful pretreatment inspection and monitoring, the reduced MP plus MTX regimen had fewer AEs compared to MP monotherapy.

Limitations of this study include the lack of prespecified QoL assessment and response evaluation at week 24. Those outcomes would likely yield significant differences among groups. Therefore, further prespecified studies of QoL and post-treatment follow-up are warranted to validate the current conclusion.

Previous GO treatment may contribute to reduced clinical response. One patient who received strabismus surgery 7 months prior to the study in group 1 (4.5 g MP) was not responsive after treatment. There were 26 patients who received glucocorticoids (i.e., oral, orbital) at least 3 months prior to treatment. Post hoc analysis showed that the CAS response was 71.4% for naïve patients and 63% for patients with previous treatment. For naïve patients (n = 63), CAS response rate was 57.1% for group 1 (n = 21), 75% for group 2 (n = 20), and 81.8% for group 3 (n = 22).

### Table 2

Continued.

| Parameters | Deteriorated Visual function | Deteriorated Appearance | Deteriorated Overall response | Deteriorated QoL | Improved Visual function | Improved Appearance | Improved Overall response | QoL-improved | ITT (n = 30) | PP (n = 22, 21, 19)* | ITT (n = 30) | PP (n = 22, 21, 19)* |
|------------|-----------------------------|-------------------------|-------------------------------|------------------|-------------------------|---------------------|-------------------------|--------------|---------------|------------------|--------------|------------------|
| Baseline   | 0.8 ± 0.4                   | 0.7 ± 0.3               | 1.0 ± 0.4                     | 0.8 ± 0.3        | 0.3 ± 0.3               | 0.6 ± 0.3          | 0.6 ± 0.3               | 0.8 ± 0.3   | 17 (56.7)     | 17 (89.5)       | 17 (56.7)     | 17 (89.5)       |
| Post-treatment | 5.8 ± 28.3                 | 69.3 ± 21.0             | 69.3 ± 21.0                   | 5.8 ± 28.3       | 69.3 ± 21.0             | 69.3 ± 21.0        | 69.3 ± 21.0             | 5.8 ± 28.3 | 16 (53.3)     | 16 (84.2)       | 16 (59.6)     | 16 (84.0)       |
| P-value     | 0.0001                      | <0.0001                 | <0.0001                       | 0.0001           | 0.0000                  | 0.0000              | 0.0000                  | 0.0001      | 0.7/1/1       | 0.7/1/1         | 0.7/1/1       | 0.7/1/1         |

**Ophthalmic parameters were analyzed by the worst eye.** *ITT (n = 22, 21, 19)*: n = 22 (MP, G1), n = 21 (reduced MP+MTX, G2) and n = 19 (MP+MTX, G3).
In summary, this is the first prospective RCT study to compare the efficacy and safety of reduced MP plus MTX vs MP monotherapy with matched 12-week time course. As most AEs were steroid dosage-dependent, we demonstrated that under careful pretreatment inspection and monitoring, reduced MP plus MTX had fewer AEs with similar efficacy. *Post hoc* subgroup analysis found that smoking interfered with treatment. Prespecified subgroup analysis should be conducted in future studies to test for subgroup superiority.

**Conclusion**

Reduced ivMP (3.0 g) plus MTX therapy was not significantly different in CAS response at week 12 but brought less steroid-related adverse effects compared with the standard 4.5 g ivMP regimen in active, moderate-to-severe GO. Therefore, we suggest reduced MP plus MTX combination therapy to lower steroid-related AEs as well as to achieve CAS response. Due to the potential side effects of MTX, clinical use should always be careful with pretreatment inspection and monitoring.

**Supplementary materials**

This is linked to the online version of the paper at https://doi.org/10.1530/ETJ-22-0017.

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

---

**Table 3** Adverse event.

| Adverse event                       | MP (G1) | Reduced MP + MTX (G2) | MP + MTX (G3) | *P*-value overall/G1 vs G2/G1 vs G3 |
|-------------------------------------|---------|-----------------------|--------------|-------------------------------------|
| Any adverse event                  | 25 (83.3%) | 15 (50%)               | 22 (73.3%)   | 0.02/0.01/0.5                    |
| Weight gain, kg*                    | 0.2 ± 2.3 | −0.3 ± 2.0             | −0.2 ± 2.3   | 0.8/1/1                            |
| ≥ 5% increment                      | 6 weeks: 2 (6.7%) | 2 (6.7%)        | 2 (6.7%)    | 1/1/1                              |
|                                    | 12 weeks: 9 (30%) | 2 (6.7%)          | 7 (23.3%)   | 0.06/0.04/0.8                     |
| ≥ 5% increment (grade 1)*          | 6 weeks: 0 | 2 (6.7%)               | 1 (3.3%)    | 0.8/0.5/1                         |
|                                    | 12 weeks: 2 (6.7%) | 2 (6.7%)         | 3 (10%)     | 1/1/1                              |
| Hypertension*                      | 6 weeks: 4 (21.1%) | 2 (8.7%)            | 0           | 0.08/0.04/0.047                  |
|                                    | 12 weeks: 5 (26.3%) | 2 (8.7%)           | 0           | 0.03/0.2/0.02                    |
| Hypokalemia*                       | 6 weeks: 4 (18.2%) | 0                   | 1 (4%)      | 0.02/0.038/0.2                   |
|                                    | 12 weeks: 5 (22.7%) | 1 (3.9%)           | 1 (4%)      | 0.06/0.08/0.08                   |
| Diabetes*                          | 6 weeks: 0 | 1 (5%)                | 0           | 1/1/-                              |
|                                    | 12 weeks: 0 | 2 (10%)               | 0           | 0.3/0.5/-                         |
| Dyslipidemia*                      | 6 weeks: 7 (35%) GR1 | 4 (18.2%) GR1     | 6 (28.6%) GR1, 2 (9.5%) GR2 | 0.3/0.3/0.6                  |
|                                    | 12 weeks: 10 (50%) GR1, 1 (5%) GR2 | 6 (27.3%) GR1       | 10 (47.5%) GR1, 2 (9.5%) GR2 | 0.2/0.1/1                   |
| Osteoporosis* (12 weeks)           | 0       | 1 (4.6%)               | 2 (8.3%)    | 1/1/1                              |
| Bone loss* (12 weeks)              | 1 (6.7%) | 2 (10%)                |             |                                   |
| Neutropenia*                       | 6 weeks: 0 | 1 (3.3%) GR2           | 2 (6.9%) GR1 | 0.3/1/0.5                  |
|                                    | 12 weeks: 0 | 1 (3.3%) GR2           | 3 (10.3%) GR1 | 0.1/1/0.2                    |
| Impairment of liver function*      | 1 (3.3%) | 0                     |             | -                                  |
| Leukocyturia (asymptomatic)*       | 6 (21.4%) | 4 (14.8%)              | 6 (20.7%)   | 0.8/0.7/1                         |
| Hyperuricemia*                     | 6 weeks: 0 | 0                     | 2 (6.7%)    | 0.3/-/0.5                        |
|                                    | 12 weeks: 2 (6.7%) | 0                  | 3 (10%)     | 0.4/0.5/1                        |
| Other                              | Cold     | 0                     | 1 (6 weeks) GR1 | -                                 |
|                                    | Facial paralysis | 1 (6 weeks) GR1 | 0           | -                                 |
|                                    | Femoral head necrosis | 0                 | 0           | -                                 |
|                                    | Insomnia  | 0                     | 1 (12 weeks) GR2 | -                                 |
|                                    | Other     | 0                     | 1 (12 weeks) GR1 | -                                 |

*New onset; *the criteria of CTCAE grade 1 for weight gain is ≥5% of baseline body weight, which was close to 3 kg in this cohort. Hypertension and diabetes were grade 2. Hypokalemia and hyperuricemia were grade 1. Asymptomatic leukocyturia was discovered by urinalysis without symptoms and did not require medical treatment. 12-week data are cumulative which includes AE that occurred at week 6. GR1, grade 1; GR2, grade 2.

Hypertension and diabetes were grade 2. Hypokalemia and hyperuricemia were grade 1. Asymptomatic leukocyturia was discovered by urinalysis without symptoms and did not require medical treatment. 12-week data are cumulative which includes AE that occurred at week 6. GR1, grade 1; GR2, grade 2.
Funding
This work is supported by grants from the National Natural Science Foundation of China (81500604, 81770782), and Innovative research team of high-level local universities in Shanghai (SSMU-ZDCX 20180401).

Author contribution statement
W Z, G N, and S W designed the trial. L S, W Z, Q J, and Y Z performed the trial. L Y, S W, W W, and G N provided helpful discussions. L S and L Y analyzed data and wrote the paper. S W and W W were responsible for research supervision, coordination, and strategy. L S, L Y, W Z, and Q J contributed equally to this work.

Acknowledgements
The authors thank Dr Mengxi Zhou for her efforts in data collection during her study in our department in 2018–2019.

References
1 Gerdning MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF & Wiersinga WM. Quality of life in patients with Graves’ ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. *Thyroid* 1997 7 885–889. (https://doi.org/10.1089/thy.1997.7.885)
2 Terwee C, Wakelkamp I, Tan S, Dekker F, Prummel MF & Wiersinga W. Long-term effects of Graves’ ophthalmopathy on health-related quality of life. *European Journal of Endocrinology* 2002 146 751–757. (https://doi.org/10.1530/eje.0.146075)
3 Wiersinga WM. Quality of life in Graves’ ophthalmopathy. *Best Practice and Research: Clinical Endocrinology and Metabolism* 2012 26 359–370. (https://doi.org/10.1016/j.beem.2011.11.001)
4 Smith TJ, Kahaly GJ, Ezr DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. *New England Journal of Medicine* 2017 376 1748–1761. (https://doi.org/10.1056/NEJMoai1614949)
5 Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdock R, Fleming JC, Fowler BT, Marocci C, Marino M, et al. Teprotumumab for the treatment of active thyroid eye disease. *New England Journal of Medicine* 2020 382 341–352. (https://doi.org/10.1056/NEJMoai1904343)
6 Kahaly GJ, Douglas RS, Holt RJ, Sile S & Smith TJ. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. *Lancet: Diabetes and Endocrinology* 2021 9 360–372. (https://doi.org/10.1016/S2213-8587(21)00056-5)
7 Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marocci C, Marino M, Vaidya B, Wiersinga WM & EUGOGO. The 2021 European Group on Graves’ ophthalmopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. *European Journal of Endocrinology* 2021 185 G43–G67. (https://doi.org/10.1530/EJE-21-0479)
8 Bartalena L, Krassas GE, Wiersinga W, Marocci C, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi I, Veronesi G, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. *Journal of Clinical Endocrinology and Metabolism* 2012 97 4454–4463. (https://doi.org/10.1210/jc.2012-2389)
9 Zhu W, Ye L, Shen L, Jiao Q, Huang F, Han B, Zhang X, Wang S, Wang W & Ning G. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with Graves’ ophthalmopathy. *Journal of Clinical Endocrinology and Metabolism* 2014 99 1999–2007. (https://doi.org/10.1210/jc.2013-3919)
10 Zang S, Ponto KA & Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. *Journal of Clinical Endocrinology and Metabolism* 2011 96 320–332. (https://doi.org/10.1210/jc.2010-1962)
11 Rubinov A, Zommer H, Aghazadeh H & Weis E. Role of methotrexate in thyroid-related orbitopathy. *Canadian Journal of Ophthalmology: Journal Canadien d’Ophthalmologie* 2018 53 34–38. (https://doi.org/10.1016/j.jcjo.2017.07.009)
12 Sipkova Z, Insull EA, David J, Turner HE, Keren S & Norris JH. Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach. *Clinical Endocrinology* 2018 89 834–839. (https://doi.org/10.1111/cei.13834)
13 Salvi M. Step-down steroid-sparing therapy in active thyroid eye disease. *Nature Reviews: Endocrinology* 2018 14 634–635. (https://doi.org/10.1038/s41574-018-0099-9)
14 Tanda ML, Plauntanida E, Masiello E, Cusini C & Bartalena L. Can combination of glucocorticoids with other immunosuppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves’ orbitopathy? *Journal of Endocrinological Investigation* 2019 42 351–352. (https://doi.org/10.1530/jo.19-01015-8)
15 Goecjea I, Alvarez C, Henriquez J, Salas K, Molina ML, Ferreira A & Gatica H. Methotrexate regulates the expression of glucocorticoid receptor alpha and beta isoforms in normal human peripheral mononuclear cells and human lymphocyte cell lines in vitro. *Molecular Immunology* 2007 44 2115–2123. (https://doi.org/10.1016/j.molimm.2006.07.030)
16 Terwee CB, Gerdning MN, Dekker FW, Prummel MF & Wiersinga WM. Development of a disease specific quality of life questionnaire for patients with Graves’ ophthalmopathy: the GO-QOL. *British Journal of Ophthalmology* 1998 82 773–779. (https://doi.org/10.1136/bjo.82.7.773)
17 Terwee CB, Dekker FW, Mourits MP, Gerdning MN, Baldeschi L, Kalmann R, Prummel MF & Wiersinga WM. Interpretation and validity of changes in scores on the Graves’ ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. *Clinical Endocrinology* 2001 54 391–398. (https://doi.org/10.1046/j.1365-2265.2001.01241.x)
18 Bartalena L & Wiersinga WM. Proposal for standardization of primary and secondary outcomes in patients with active, moderate-to-severe Graves’ orbitopathy. *European Thyroid Journal* 2020 9 (Supplement 1) S3–S16. (https://doi.org/10.1515/etj-2019-1006)
19 Kahaly GJ, Riedl M, Konig J, Pitz S, Ponto K, Diana T, Kampmann E, Kolbe E, Eckstein A, Moeller LC, et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. *Lancet: Diabetes and Endocrinology* 2018 6 287–298. (https://doi.org/10.1016/S2213-8587(18)30020-2)
20 Chalvatzis NT, Tzamalis AK, Kalantizis GK, El-Hindy N, Dimitrakos SA & Potts MJ. Safety and efficacy of combined immunosuppression and orbital radiotherapy in thyroid-related restrictive myopathy: two-center experience. *European Journal of Ophthalmology* 2014 24 953–959. (https://doi.org/10.5530/ejo.500463)
21 Rajendram R, Taylor PN, Wilson VJ, Harris N, Morris OC, Tomlinson M, Yarrow S, Garrott H, Herbert HM, Dick AD, et al. Combined immunosuppression and radiotherapy in thyroid eye disease (CIREDT): a multicentre, 2 x 2 factorial, double-blind, randomised controlled trial. *Lancet: Diabetes and Endocrinology* 2018 6 299–309. (https://doi.org/10.1016/S2213-8587(18)30021-4)
22 Kahaly G, Schrezenmeir J, Krause U, Schweikert B, Meurer S, Muller W, Dennebaum R & Beyer J. Ciclosporin and prednisone v. prednisone in treatment of Graves’ orbitopathy: a controlled, randomised and prospective study. *European Journal of Clinical Investigation* 1986 16 415–422. (https://doi.org/10.1111/j.1365-2362.1986.tb01016.x)
23 Prummel MF, Mourits MP, Berghout A, Kremning EJ, van der Gaag R, Koornneef L & Wiersinga WM. Prednisone and cyclosporine in
the treatment of severe Graves’ ophthalmopathy. New England Journal of Medicine 1989 321 1353–1359. (https://doi.org/10.1056/NEJM198911163212002)

24 Wang G & Peng X. A review of clinical applications and side effects of methotrexate in ophthalmology. Journal of Ophthalmology 2020 2020 1537689. (https://doi.org/10.1155/2020/1537689)

25 Rathinam SR, Gonzales JA, Thundikandy R, Kanakath A, Murugan SB, Bedoui Y, Guillot X, Selambarom J, Guiraud P, Jaffar-Bandjee MC, Ralandison S & Gasque P. Methotrexate an old drug with new tricks. International Journal of Molecular Sciences 2019 20 5023. (https://doi.org/10.3390/ijms20205023)

26 Emery P, Sebba A & Huizinga TW. Biologic and oral disease-modifying anti-rheumatic drug monotherapy in rheumatoid arthritis. Annals of the Rheumatic Diseases 2013 72 1897–1904. (https://doi.org/10.1136/annrheumdis-2013-203485)

27 Bedoui Y, Guillot X, Selambarom J, Guiraud P, Giry C, Jaffar-Bandjee MC, Ralandison S & Gasque P. Methotrexate an old drug with new tricks. International Journal of Molecular Sciences 2019 20 5023. (https://doi.org/10.3390/ijms20205023)

28 Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacological Reviews 2005 57 163–172. (https://doi.org/10.1124/pr.57.2.3)

29 Fairbanks LD, Buckemann K, Qiu Y, Hawrylowicz CM, Richards DF, Swaminathan R, Kirschbaum B & Simmonds HA. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? Biochemical Journal 1999 342 143–152. (https://doi.org/10.1042/bj3420143)

30 Hasko G & Cronstein B. Regulation of inflammation by adenosine. Frontiers in Immunology 2013 4 85. (https://doi.org/10.3389/fimmu.2013.00085)

31 Varani K, Padovan M, Vincenzi E, Targa M, Trotta E, Govoni M & Borre PA. A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. Arthritis Research and Therapy 2011 13 R197. (https://doi.org/10.1186/ar3527)

32 Miranda-Carus ME, Balsa A, Benito-Miguel M, Perez de Ayala C & Martin-Mola E. IL-15 and the initiation of cell contact-dependent synovial fibroblast-T lymphocyte cross-talk in rheumatoid arthritis: effect of methotrexate. Journal of Immunology 2004 173 1463–1476. (https://doi.org/10.4049/jimmunol.173.2.1463)

33 Lanzolla G, Sabini E, Profillo MA, Mazzi B, Strameli A, Rocchi R, Menconi E, Leo M, Nardi M, Vitti P, et al. Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study. Journal of Endocrinological Investigation 2018 41 1417–1423. (https://doi.org/10.1007/s40638-018-0915-z)

34 Sabini E, Mazzi B, Profillo MA, Mautone T, Casini G, Rocchi R, Ionnì I, Menconi E, Leo M, Nardi M, et al. High serum cholesterol is a novel risk factor for Graves’ orbitopathy: results of a cross-sectional study. Thyroid 2018 28 386–394. (https://doi.org/10.1089/thy.2017.0430)

35 Lanzolla G, Vannucchi G, Ionnì I, Campi I, Sileo f, Lazzeroni E & Marino M. Cholesterol serum levels and use of statins in Graves’ orbitopathy: a new starting point for the therapy. Frontiers in Endocrinology 2019 10 933. (https://doi.org/10.3389/fendo.2019.00933)

36 Mangoni AA, Baghdadi LR, Shanahan EM, Wiese MD, Tommassi S, Elliot D & Woodman RJ. Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study. Therapeutic Advances in Musculoskeletal Disease 2017 9 213–229. (https://doi.org/10.1177/1759720X17719850)

37 Woodman RJ, Baghdadi LR, Shanahan M & Mangoni AA. The temporal relationship between arterial stiffening and blood pressure is modified by methotrexate treatment in patients with rheumatoid arthritis. Frontiers in Physiology 2017 8 593. (https://doi.org/10.3389/fphys.2017.00593)

38 Titte SR, Laubner K, Schmid SM, Kress S, Merger S, Karges W, Wosch FJ, Altmeier M, Pavel M, Holf RW, et al. Immune-checkpoint inhibitor-associated diabetes compared to other diabetes types – a prospective, matched control study. Journal of Diabetes 2021 13 1007–1014. (https://doi.org/10.10111/jid.2021.0407.13215)

39 Li JX & Cummins CL. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nature Reviews: Endocrinology 2022 18 540–557. (https://doi.org/10.1038/s41574-022-00683-6)

40 Solomon DH, Glynn RJ, Karlson EW, Lu F, Corrigan C, Colls J, Xu C, MacFadyen J, Barthaiya M, Beltriner N, et al. Adverse effects of low-dose methotrexate: a randomized trial. Annals of Internal Medicine 2020 172 369–380. (https://doi.org/10.7326/M19-3369)

Received in final form 17 July 2022
Accepted 26 July 2022
Accepted Manuscript published online 26 July 2022